Farmacia Hospitalaria y Farmacogenómica

Escudero-Vilaplana V; Guisado-Gil AB; Santos-Ramos B; Herranz A.

Development and consensus of a dashboard model to evaluate research activity in Spanish Hospital Pharmacy Services.

FARMACIA HOSPITALARIA. 2024; 48 Suppl 1: [doi:10.1016/j.farma.2023.12.007]

Escudero-Vilaplana, V; Guisado-Gil, AB; Santos-Ramos, B; Herranz, A.

Development and consensus of a dashboard model to evaluate research activity in Spanish Hospital Pharmacy Services

FARMACIA HOSPITALARIA. 2024; 48: 28-34 [doi:10.1016/j.farma.2024.03.006]

Gómez-Costas D; Romero-Jiménez RM; Lobato-Matilla ME; Culebras R; González JA; Herrero-Bermejo S; Herranz-Alonso AM; Sanjurjo-Saez M.

Detection and reduction of errors in parenteral nutrition compounding through gravimetric and product control.

FARMACIA HOSPITALARIA. 2024; 48(3): 116-121 [doi:10.1016/j.farma.2023.11.007]

de Lorenzo-Pinto, A; Redondo-Galán, C; García-González, X; Fernández-Alvarez, C; Andueza-Lillo, J; Sanjurjo-Sáez, M.

Presence of metallic components in transdermal drug delivery systems and risk of skin burns

FARMACIA HOSPITALARIA. 2024; 48(3): 129-132 [doi:10.1016/j.farma.2024.02.010]

Gómez-Costas, D; Romero-Jiménez, RM; Lobato-Matilla, ME; Culebras, R; González, JA; Herrero-Bermejo, S; Herranz-Alonso, AM; Sanjurjo, M.

Detection and reduction of errors in parenteral nutrition compounding through gravimetric and product control

FARMACIA HOSPITALARIA. 2024; 48(3): 116-121 [doi:10.1016/j.farma.2024.02.014]

de Lorenzo-Pinto A; Redondo-Galán C; García-González X; Fernández-Álvarez C; Andueza-Lillo J; Sanjurjo-Sáez M.

Presence of metallic components in transdermal drug delivery systems and risk of skin burns.

FARMACIA HOSPITALARIA. 2024; 48(3): 129-132 [doi:10.1016/j.farma.2023.11.003]

Salvador-Martín S; Rubbini G; Vellosillo P; Zapata-Cobo P; Velasco M; Palomino LM; Clemente S; Segarra O; Moreno-Álvarez A; Fernández-Lorenzo A; Pérez-Moneo B; Montraveta M; Sánchez C; Tolín M; Loverdos I; Fobelo MJ; Navas-López VM; Magallares L; García-Romero R; Torres-Peral R; Rodríguez A; Bossacoma F; Merino-Bohórquez V; Salcedo E; Álvarez R; Dopazo A; Sanjurjo-Sáez M; López-Fernández LA.

Blood gene expression biomarkers of response to anti-TNF drugs in pediatric inflammatory bowel diseases before initiation of treatment.

BIOMEDICINE & PHARMACOTHERAPY. 2024; 173: 116299-116299 Nº de citas: 2 [doi:10.1016/j.biopha.2024.116299]

Clemente-Bautista, S; Trocóniz, IF; Segarra-Cantón, O; Salvador-Marín, S; Parramón-Teixidó, CJ; Alvarez-Beltrán, M; López-Fernández, LA; Colom, H; Cabañas-Poy, MJ; Gorgas-Torner, MQ; Miarons, M.

The Effect of Polymorphisms and Other Biomarkers on Infliximab Exposure in Paediatric Inflammatory Bowel Disease: Development of a Population Pharmacokinetic Model

PEDIATRIC DRUGS. 2024; 26(3): 331-346 Nº de citas: 2 [doi:10.1007/s40272-024-00621-1]

Melero, R; Torroba-Sanz, B; Goicoechea, M; Sousa-Casasnovas, I; Barrio, J; García-Prieto, A; Rodriguez-Benitez, P; García-González, X; Sanjurjo-Sáez, M.

Treatment with Rasburicase in Hospitalized Patients with Cardiorenal Syndrome: Old Treatment, New Scenario

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2024; 25(6): [doi:10.3390/ijms25063329]

Morillo Verdugo R; Vicente Escrig E; Murillo Izquierdo M; Ibarra Barrueta O; Taberner Bonastre P; Fernández-Llamazares CM.

Analisis de la evolución de la atención farmacéutica al paciente externo en los servicios de farmacia hospitalaria en España tras la puesta en marcha y desarrollo de la iniciativa MAPEX.

Journal Of Healthcare Quality Research. 2024; 39(2): 65-79 Nº de citas: 2 [doi:10.1016/j.jhqr.2023.11.002]

Vicente-Escrig E; Bonastre PT; Barrueta OI; Izquierdo MM; Fernández-Llamazares CM; Morillo-Verdugo R.

[Translated article] Analysis 2016-2021 of the development of the MAPEX outpatient pharmaceutical care Project by Regions in Spain.

FARMACIA HOSPITALARIA. 2024; 48(2): 64-69 Nº de citas: 3 [doi:10.1016/j.farma.2023.11.001]

Vicente-Escrig E; Taberner Bonastre P; Ibarra Barrueta O; Murillo Izquierdo M; Fernández-Llamazares CM; Morillo-Verdugo R.

Analysis 2016-2021 of the development of the MAPEX outpatient pharmaceutical care Project by regions in Spain.

FARMACIA HOSPITALARIA. 2024; 48(2): 64-69 [doi:10.1016/j.farma.2023.08.007]

Jiménez, RMR; Pinto, PH; Domínguez, MC; Mata, SA; Bellmunt, A; Prades, M; Arumi, D; Hernández-Martín, I; Herrera-Lasso, V; Llevat, N; Juste, AD; Laserna, FJR.

Cost-Effectiveness Analysis of Abrocitinib Compared with Other Systemic Treatments for Severe Atopic Dermatitis in Spain

Pharmacoeconomics-Open. 2024; : Nº de citas: 4 [doi:10.1007/s41669-023-00459-2]

González, MM; Sanz-Pastor, AG; Gómez, RA; Torrecilla, NB; Moreno, DM; Fernández, LG; Rivas, AM; Guerra, AL; Alvarez, R; Arranz, JA; Rodas, IM; Escudero, V; Sanjurjo, M; Vallejo, JM; Martín, M; Albarrán, OG.

Endocrine Adverse Events Related To Immune Checkpoint Inhibitor Treatment: Relationship Between Antibodies and Severity of Thyroid Dysfunction

Endocrine Metabolic & Immune Disorders-Drug Targets. 2024; 24(14): 1628-1639 Nº de citas: 1 [doi:10.2174/0118715303280679240206100137]

Parra, AP; Ramos, N; Perurena-Prieto, J; Manrique-Rodríguez, S; Climente, M; Quintanilla, LG; Escolano, A; Miarons, M.

Pharmacokinetics of eculizumab in adult and pediatric patients with atypical hemolyticuremic syndrome and C3 glomerulopathy

FARMACIA HOSPITALARIA. 2024; 48(1): 16-22 [doi:10.1016/j.farma.2023.07.009]

Parra, AP; Ramos, N; Perurena-Prieto, J; Manrique-Rodríguez, S; Climente, M; Quintanilla, LG; Escolano, A; Miarons, M.

[Translated article] Pharmacokinetics of eculizumab in adult and pediatric patients with atypical hemolytic uremic syndrome and C3 glomerulopathy

FARMACIA HOSPITALARIA. 2024; 48(1): 16-22 [doi:10.1016/j.farma.2023.09.009]

Escudero-Vilaplana, V; Collado-Borrell, R; De Castro, J; Insa, A; Martinez, A; Fernandez, E; Sullivan, I; Flores, A; Arrabal, N; Carcedo, D; Manzaneque, A.

Cost-effectiveness of adjuvant atezolizumab versus best supportive care in the treatment of patients with resectable early-stage non-small cell lung cancer and overexpression of PD-L1

Journal of Medical Economics. 2023; 26(1): 445-453 Nº de citas: 4 [doi:10.1080/13696998.2023.2188844]

Valerio, M; Veintimilla, C; Rodriguez, C; de la Villa, S; Sanchez-Somolinos, M; Cerezales, M; Crespo, C; Rodriguez, S; Adan, I; Chamorro, E; Rossello, I; Munoz, P.

Cost analysis of disease including treatment with dalbavancin in a Spanish hospital: ECODAL ANALYSIS

Journal of Medical Economics. 2023; 26(1): 463-472 Nº de citas: 4 [doi:10.1080/13696998.2023.2190704]